Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION (INCY)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 10/23 10:00:00 pm
113.48 USD   -0.62%
10:55a CALITHERA BIOSC : Announces First Patient Treated in Phase 1 Cohort ..
10/12 INCYTE : to Report Third Quarter Financial Results
10/06 NASDAQ 100 MOVE : Cost, incy
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on INCYTE CORPORATION
10:55a CALITHERA BIOSCIENCES : Announces First Patient Treated in Phase 1 Cohort of INC..
10/19 INCYTE : and Cancer Support Community Delaware Announce the Establishment of the..
10/17 IBD Announces First Annual Biotech Innovator Awards
10/12 INCYTE : to Report Third Quarter Financial Results
10/07 NEXTERA ENERGY : Natixis Asset Management Has Lifted Its Incyte Corp. (INCY) Hol..
10/06 NASDAQ 100 MOVERS : Cost, incy
10/06 INCYTE : and Cancer Support Community Delaware Announce the Establishment of the..
09/21 INCYTE : Health
09/21 INCYTE : Merus Intellectual Property Portfolio Expands with Two New Patents For ..
09/19 ALEXION PHARMACEUTICALS : Adds Paul A. Friedman, M.D. To Its Board of Directors
09/18 ALEXION PHARMACEUTICALS, INC. (NASDA : ALXN) Files An 8-K Departure of Directors..
09/14 INCYTE : Supports the Myeloproliferative Neoplasm MPN Community During Blood Can..
09/14 INCYTE : Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Mo..
09/14 INCYTE : Pathology practice here to acquire Oregon group
09/12 INCYTE CORP : Other Events (form 8-K)
09/12 MERCK AND : Incyte chalk up promising melanoma data for Keytruda-epacadostat com..
09/12 INCYTE : Merck and Incyte present promising results of a combination cancer trea..
09/09 INCYTE : Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Ep..
09/08 INCYTE : Announces Pricing of Public Offering of 4,945,000 Shares of Common Stoc..
09/07 INCYTE : Announces Proposed Public Offering of 4,945,000 Shares of Common Stock
09/01 INCYTE : Supports the Myeloproliferative Neoplasm (MPN) Community During Blood C..
09/01 INCYTE : Lilly planning early re-file for JAK inhibitor baricitinib
08/31 FDA GRANTS ELI LILLY AND CO (NYSE : LLY) Baricitinib Faster Time Frame For Resub..
08/31 INCYTE : New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) ..
08/25 INCYTE : Governor Carney Coordinates Support for Basic Needs Closets for Student..
08/17 INCYTE : Forbes Magazine Names Incyte One of the World's Most Innovative Compani..
08/16 INCYTE : Scientist Behind Incyte's Jakafi Ready to Strike Big in Delaware Again
08/15 INCYTE : founder gets $474K from Delaware to fund new cancer drug company Prelud..
08/10 INCYTE : Forbes Magazine Names Incyte One of the World’s Most Innovative C..
08/09 Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recen..
08/08 INSIDER TRADING ACTIVITY INCYTE CORP : INCY) – Insider Sold 3,000 shares o..
08/03 INCYTE : New Pharmacokinetics Data Have Been Reported by Investigators at Incyte..
08/03 ELI LILLY AND : Lilly and Incyte Provide Update on Baricitinib
08/02 INCYTE : posts loss for quarter, but sees strong sales for blockbuster drug Jaka..
08/01 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
08/01 INCYTE CORPORATION (NASDAQ : INCY) reported earnings of ($0.06) per share missin..
08/01 INCYTE CORPORATION : Investor Network: Incyte Corporation to Host Earnings Call
08/01 INCYTE : reports 2Q loss
08/01 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
08/01 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
08/01 INCYTE : Reports 2017 Second-Quarter Financial Results and Updates on Key Clinic..
07/29 REGENERON PHARMACEUTICALS : U.S. Court of Appeals for the Federal Circuit Affirm..
07/27 INCYTE : Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib..
07/27INCYTE CORPORATION : half-yearly earnings release
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/22 INCYTE : Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib..
07/21 INSIDER TRADING ACTIVITY INCYTE CORP : INCY) – EVP Sold 6,485 shares of St..
07/20 INCYTE : Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib..
07/13 ELI LILLY AND : Japan Ministry of Health, Labor and Welfare MHLW Grants Marketin..
07/11 INCYTE : to Report Second Quarter Financial Results
07/06 INCYTE : Lillys Olumiant, spurned by FDA, gets nod from NICE
07/05 NETWORKNEWSBREAKS – AEGIS CAPI : Cnce)
07/05 INCYTE : & Lilly`s Olumiant Gets Marketing Approval in Japan
07/03 INCYTE : Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing App..
06/22 ELI LILLY AND : New Safety and Long-Term Efficacy Data from Baricitinib Clinical..
06/20 INCYTE : Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arth..
06/20 INCYTE : New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials..
06/16 INCYTE : New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials..
06/15 INCYTE : Analyst and Investor Event to Highlight Clinical Data Presentations fro..
06/15 INCYTE : Updated Data from ECHO-202 Trial of Incyte's Epacadostat in Combination..
06/14 INCYTE : Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arth..
06/09 INCYTE : Researchers at Incyte Corporation Report New Data on Medicinal Chemistr..
06/07 INCYTE : to Present at Upcoming Investor Conferences
06/06 INCYTE CORPORATION : Corporate News Blog - Incyte and Merck Release Phase-1/2 Cl..
06/05 INCYTE : Analyst and Investor Event to Highlight Clinical Data Presentations fro..
06/05 INCYTE : Updated Data from ECHO-202 Trial of Epacadostat in Combination with KEY..
06/04 INCYTE : Merck early-stage study of cancer drug combo shows promise
06/03 INCYTE : Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates ..
05/30 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Submission of Matters to a Vote ..
05/25 INCYTE : New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Ep..
05/25 INCYTE : First Data from Combination of Epacadostat with Opdivo® nivolumab Will ..
05/22 INCYTE : to Present at Upcoming Investor Conferences
05/18 INCYTE : Vaults on Drug Test Results
05/18 S&P 500 MOVERS : Csco, incy
05/18 NASDAQ 100 MOVERS : Csco, incy
1  2  3  4  5  6  7Next
Financials ($)
Sales 2017 1 471 M
EBIT 2017 -79,4 M
Net income 2017 -174 M
Finance 2017 394 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 319,50
EV / Sales 2017 16,1x
EV / Sales 2018 13,8x
Capitalization 24 054 M
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 149 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION13.88%24 054
QUINTILES IMS HOLDINGS INC35.48%22 162
LONZA GROUP57.01%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522
SEATTLE GENETICS, INC.21.02%9 134